Senhwa Biosciences, Inc. (TPEX:6492)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
38.10
+0.55 (1.46%)
Aug 19, 2026, 10:20 AM CST

Senhwa Biosciences Financials Overview

Millions TWD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
1.051.071110.55
Revenue Growth
5.00%7.00%0%0%81.82%-10.86%
Gross Profit
0.440.520.480.550.510.32
Operating Income
-306.08-278.26-306.19-311.11-356.12-346.32
Net Income
-296.6-264.77-293.75-296.31-349.63-329.26
Earnings Per Share
-3.32-2.97-3.29-3.32-3.92-3.67
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
636.92771.781,0261,3191,6192,033
Total Debt
17.9222.12159.616.1615.38
Net Cash (Debt)
619.01749.671,0111,3091,6032,017
Net Cash Growth
-28.68%-25.85%-22.78%-18.33%-20.54%-14.14%
Net Cash Per Share
6.928.4011.3414.6817.9722.50

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-256.71-248.46-294.22-294.4-399.97-300.05
Capital Expenditures
-0.51-0.28-1.95-4.61-0.37-0.24
Free Cash Flow
-257.22-248.74-296.17-299-400.34-300.29
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
42.19%48.60%47.70%55.20%50.50%58.73%
Operating Margin
-29150.19%-26005.51%-30619.10%-31111.10%-35611.50%-62966.54%
Pretax Margin
-28120.19%-24620.19%-29246.40%-29504.50%-34826.00%-59699.45%
Profit Margin
-28247.43%-24744.77%-29374.50%-29630.60%-34963.20%-59864.91%
FCF Margin
-24497.24%-23246.45%-29617.30%-29900.10%-40034.00%-54597.64%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Forward PE
-10.2310.2310.2310.239.84
PS Ratio
3196.613667.453879.594539.575140.4216962.14